Alnylam prepares to land first RNAi drug approval
Nature Reviews Drug Discovery 17, 156 (2018).
doi:10.1038/nrd.2018.20
Author: Chris Morrison
With Alnylam's rare disease drug candidate patisiran nearing the regulatory finish line, the RNA interference community is now turning its attention to next-generation delivery technology to solidify the future of the emerging modality.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Chris Morrison Tags: News and Analysis Source Type: research
More News: Drugs & Pharmacology | Rare Diseases